Charles M. Perou

This study shows that daraxonrasib, a pan-RAS(on) inhibitor, effectively inhibits TNBC cell proliferation and tumor growth, either alone or in combination with a MEK inhibitor.

This paper shows that combining MERTK inhibition with cyclophosphamide enhances anti-tumor immunity in basal-like TNBC by reprogramming macrophages and promoting CD4 T cell responses.

This paper uses mouse mammary tumor data to train machine learning models predicting human breast cancer survival and treatment response.

This study shows vandetanib enhances tamoxifen sensitivity in ER+ breast cancer by reprogramming ER gene regulation and kinase networks, identifying adaptive resistance pathways and response signatures.

The paper shows that combining anti-CSF-1R therapy with chemotherapy and anti-PD-1 improves immune response in metastatic TNBC by reducing macrophages and increasing T/B cell infiltration.

This study identifies regulatory elements that switch from silencers to enhancers in breast cancer cells using single-cell ATAC-seq and RNA-seq data.

This paper introduces HistoXGAN, a GAN that reconstructs cancer histology from latent features, showing it retains tumor grade, histologic subtype, and gene expression patterns across 29 cancer types.

This study quantifies kinase protein abundance in human tissues using proteomic mass spectrometry, revealing heterogeneity in breast cancer subtypes and enabling clinical applications.

This study shows that combining nanoformulated TLR7/8 agonist and PI3K delta inhibitor with radiotherapy improves anti-tumor activity in TNBC by modulating the tumor microenvironment.

The paper investigates race-specific germline genetic associations with breast cancer recurrence scores using GReX and finds differential associations between germline variants and CRS in Black and White patients.

The paper analyzes rare copy number variants (CNVs) in breast cancer cases and controls, identifying associations with known and novel susceptibility loci.

The paper analyzes DNA alterations across cell cycle activity levels in 9,515 cancer patients, finding that mutation frequencies vary with cell cycle activity and that cell cycle activity is a prognostic factor.

SCDC improves bulk RNA-seq deconvolution by integrating multiple scRNA-seq reference datasets, achieving better accuracy in cell-type decomposition.

This paper introduces I-Boost, a method that improves survival time prediction by integrating multiple genomics data types with clinical variables, showing better accuracy than existing methods.